MicroRNAs as anti-cancer therapy

Current Pharmaceutical Design

Volumn 20, Issue 33, 2014, Pages 5328-5335

  Garofalo, Michela ^a   Di Leva, Gianpiero ^a   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer; microRNAs

Indexed keywords

ANTIMIR OLIGONUCLEOTIDE; MICRORNA; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GENE THERAPY; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84926355098     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140128211346     Document Type: Article

References (109)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
2. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901-6.
3. Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates micro RNA processing. Nature. 2003; 425: 415-9.
4. Bohnsack MT, Czaplinski K, Gorlich D 2004. Exportin 5 is a Ran GTP-dependent ds RNA-binding protein that mediates nuclear export of pre-mi RNAs. RNA 10: 185-91.
5. Huntzinger, E. & Izaurralde, E. Gene silencing by microRNAs: contributions of translational repression and m RNA decay. Nature Rev. Genet 2011; 12: 99-110.
6. Bartel DP. Micro RNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
7. Rodriguez A, Griffiths-Jones S, Ashurst JL, et al. Identification of mammalian micro RNA host genes and transcription units. Genome Res 2004; 14: 1902-10
8. Han R, Kan Q, Sun Y et al. Mi R-9 promotes the neural differentiation of mouse bone marrow mesenchymal stem cells via targeting zinc finger protein 521. Neurosci Lett 2012; 515: 147-52
9. D'Urso PI, D'Urso OF, Storelli C, et al. mi R-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. Int J Oncol 2012; 41: 228-34.
10. Garofalo M, Romano G, Di Leva G, et al. EGFR and MET receptor tyrosine kinase-altered micro RNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011; 18: 74-82
11. Boettger T, Braun T. A new level of complexity: the role of microRNAs in cardiovascular development. Circ Res 2012; 110: 1000-13
12. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes mi R15 and mi R16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
13. Lu J, Getz G, Miska EA, et al. Micro RNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
14. Volinia S, Calin GA, Liu CG, et al. A micro RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
15. Seca H, Lima RT, Lopes-Rodrigues V, et al. Targeting mi R-21 Induces Autophagy and Chemosensitivity of Leukemia Cells. Curr Drug Targets 2013; 14: 1135-43.
16. Jardin F, Figeac M. Micro RNAs in lymphoma, from diagnosis to targeted therapy. Curr Opin Oncol 2013; 25(5): 480-6
17. Bao L, Yan Y, Xu C, et al. Micro RNA-21 suppresses PTEN and h Sulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 2013; 337: 226-36.
18. Chao TF, Xiong HH, Liu W, et al. Mi R-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and h MSH2. J Huazhong Univ Sci Technolog Med Sci 2013; 33: 525-9.
19. Li J, Zhang Y, Zhang W, et al. Genetic Heterogeneity of Breast Cancer Metastasis May Be Related to mi R-21 Regulation of TIMP-3 in Translation. Int J Surg Oncol 2013; 2013: 875078.
20. Tu H, Sun H, Lin Y, et al. Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via mi R-21. Curr Pharm Des 2013 Jul 19. [Epub ahead of print].
21. Guancial EA, Bellmunt J, Yeh S, et al. The evolving understanding of micro RNA in bladder cancer. Urol Oncol 2013: S1078-1439: 00200-7.
22. Vicinus B, Rubie C, Stegmaier N, et al. mi R-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: Significance of their regulation. Oncol Rep 2013 Jul 1. [Epub ahead of print].
23. Vang S, Wu HT, Fischer A, et al. Identification of ovarian cancer metastatic mi RNAs. PLo S One 2013; 8(3): e58226.
24. Gombos K, Juhasz K, Kovacs K, et al. Anticancer Res 2013; 33: 2561-7.
25. Jiang M, Zhang P, Hu G, et al. Mol Cell Biochem 2013 Jul 24. [Epub ahead of print]
26. Kawakita A, Yanamoto S, Yamada SI, et al. Micro RNA-21 Promotes Oral Cancer Invasion via the Wnt/_-Catenin Pathway by Targeting DKK2. Pathol Oncol Res 2013 [Epub ahead of print]
27. Roy S, Yu Y, Padhye SB, et al. Difluorinated-Curcumin (CDF) Restores PTEN Expression in Colon Cancer Cells by Down-Regulating mi R-21. PLo S One 2013; 8: e68543.
28. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-mi R155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-9.
29. Zhang X, Li M, Zuo K, et al. J Clin Endocrinol Metab 2013; 98: E1305-13.
30. Jiang S, Zhang HW, Lu MH, et al. Cancer Res 2010; 70: 3119-27.
31. Kono H, Nakamura M, Ohtsuka T, Nagayoshi Y, et al. Oncol Rep 2013; 30: 17-24.
32. Trotta R, Chen L, Costinean S, et al. Overexpression of mi R-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 2013; 121: 3126-34.
33. Ota A, Tagawa H, Karnan S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 3087-3095.
34. Iorio MV, Ferracin M, Liu CG, et al. Micro RNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070
35. Calin GA, Ferracin M, Cimmino A, et al. A micro RNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-01
36. Garzon R, Volinia S, Liu CG, et al. Micro RNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-9.
37. Manni I, Artuso S, Careccia S, et al. The micro RNA mi R-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 2009; 23: 3957-66.
38. Wang F, Li T, Zhang B, et al. Micro RNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013; 434: 688-94.
39. Huang G, Nishimoto K, Zhou Z, et al. mi R-20a encoded by the mi R-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012; 72: 908-16.
40. Wu Q, Yang Z, Wang F, et al. Mi R-19b/20a/92a regulates the selfrenewal and proliferation of gastric cancer stem cells. J Cell Sci 2013. [Epub ahead of print].
41. Di Leva G, Gasparini P, Piovan C, et al. Micro RNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010; 102: 706-21.
42. Pichiorri F, Palmieri D, De Luca L, et al. In vivo NCL targeting affects breast cancer aggressiveness through mi RNA regulation. J Exp Med 2013; 210: 951-68.
43. Visone R, Russo L, Pallante P, et al. Micro RNAs (mi R)-221 and mi R-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007; 14: 791-8.
44. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc finger-micro RNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68: 2745-54.
45. Di Martino MT, Gullà A, Cantafio ME, et al. In vitro and in vivo anti-tumor activity of mi R-221/222 inhibitors in multiple myeloma. Oncotarget 2013; 4: 242-55.
46. Rommer A, Steinleitner K, Hackl H, et al. Overexpression of primary micro RNA 221/222 in acute myeloid leukemia. BMC Cancer 2013; 13: 364.
47. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of mi RNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17(15): 1298-307.
48. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of mi R-34a by aberrant Cp G methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-600.
49. Chim CS, Wan TS, Wong KY, et al. Methylation of mi R-34a, mi R-34b/c, mi R-124-1 and mi R-203 in Phnegative myeloproliferative neoplasms. J Transl Med 2011; 9: 197.
50. Wang Z, Chen Z, Gao Y. DNA hypermethylation of micro RNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther 2011; 11: 490-6.
51. Garofalo M, Jeon YJ, Nuovo GJ, et al. Mi R-34a/c-Dependent PDGFR-_/_ Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLo S One 2013; 8: e67581.
52. Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the micro RNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-54.
53. Iorio MV, Visone R, Di Leva G, et al. Micro RNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
54. Zhang H, Su SB, Zhou QM, et al. Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells. Ai Zheng 2009; 28: 493-9.
55. Elson-Schwab I, Lorentzen A, Marshall CJ. Micro RNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLo S One 2010; 5 pii: e13176.
56. Zhang HF, Xu LY, Li EM. A Family of Pleiotropically Acting Micro RNAs in Cancer Progression, mi R-200: Potential Cancer Therapeutic Targets. Curr Pharm Des 2013 [Epub ahead of print]
57. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growthand response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-29.
58. Cui XY, Guo YJ, Yao HR. Analysis of micro RNA in drug-resistant breast cancer cell line MCF-7/ADR. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 1813-5.
59. Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127: 1785-9.
60. Rui W, Bing F, Hai-Zhu S, et al. Identification of micro RNA profiles in docetaxelresistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 2010; 14: 206-14.
61. Sampson VB, Rong NH, Han J, et al. Micro RNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-70.
62. Lee YS, Dutta A. The tumor suppressor micro RNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21: 1025-30.
63. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 micro RNA family. Cell 2005; 120: 635-47.
64. Klein U, Lia M, Crespo M, et al. The DLEU2/mi R-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
65. Lee HK, Bier A, Cazacu S, et al. Micro RNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLo S One 2013; 8: e54652.
66. Pagliuca A, Valvo C, Fabrizi E, et al. Analysis of the combined action of mi R-143 and mi R-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2013; 32: 4806-4813.
67. Noguchi S, Yasui Y, Iwasaki J, et al. Replacement treatment with micro RNA-143 and-145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways Cancer Lett 2013; 328: 353-61.
68. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor mi R-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
69. Meng W, Jiang L, Lu L, et al. Anti-mi R-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biol Int 2012; 36: 653-9.
70. Feng B, Wang R, Chen LB. Mi R-100 resensitizes docetaxelresistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012; 317: 184-91.
71. Liang Z, Li Y, Huang K, et al. Regulation of mi R-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 2011; 28: 3091-100.
72. Liu YJ, Lin YF, Chen YF, et al. Micro RNA-449a enhances radiosensitivity in CL1-0 lung adenocarcinoma cells. PLo S One 2013; 8: e62383.
73. Characiejus D, Hodzic J, Jacobs JJ. "First do no harm" and the importance of prediction in oncology. EPMA J 2010; 1: 369-75.
74. Wang Z, Han J, Cui Y, et al. Circulating micro RNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy. Med Hypotheses 2013; 81: 41-3.
75. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
76. Bader AG, Brown D, Stoudemire J, et al. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-6.
77. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of si RNAs reduces "off-target" transcript silencing. RNA 2006; 12: 1197-205.
78. Aagaard L & Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv Rev 2007; 59: 75-86.
79. Zhao X, Pan F, Holt CM, et al. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Exp. Opin. Drug Deliv 2009; 6: 673-86.
80. Malik R & Roy L. Design and development of antisense drugs. Exp. Opin. Drug Discov 2008; 3: 1189-207.
81. Chiarantini L, Cerasi A, Fraternale A, et al. Comparison of a novel delivery systems for antisense peptide nucleic acids. J. Control. Release 2005; 109: 24-36.
82. Zuhorn, I.S., Engberts, J.B. & Hoeckstra, D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur. Biophys. J 2007; 36: 349-362.
83. Chirila TV, Rakoczy PE, Garrett KL, et al. The use of synthethic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002; 23; 321-342.
84. Rosi NL, Giljohann DA, Thaxton CS, et al. Oligonucleotidemodified gold nanoparticles for intracellular gene regulation. Science 2006; 312: 1027-30.
85. Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting sc Fv deliver si RNA and mi RNA for cancer therapy. Mol Ther 2010; 18: 1650-56.
86. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor micro RNA-34. Cancer Res 2010; 70: 5923-30.
87. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor micro RNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19: 1116-22.
88. Wu Y, Crawford M, Mao Y, et al. Therapeutic Delivery of Micro RNA-29b by Cationic Lipoplexes for Lung Cancer. Mol Ther Nucleic Acids 2013; 2: e84.
89. Sioud M, Furset G, Cekaite L. Suppression of immunostimulatory si RNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun 2007; 361: 122-6.
90. Eberle F, Giessler K, Deck C, et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol 2008; 180: 3229-37.
91. Michelfelder, S. & Trepel, M. Adeno-associated viral vectors and their redirection to cell-type specificreceptors. Adv. Genet 2009; 67: 29-60.
92. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic micro RNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-17.
93. Yang X, Haurigot V, Zhou S, Luo G, Couto LB. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus micro RNA cluster. Hepatology 2010; 52: 1877-87.
94. Henry SP, Beattie G, Yeh G, Chappel A, et al. Int Immunopharmacol. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide 2002; 2: 1657-66.
95. Snøve O Jr, Rossi JJ. Chemical modifications rescue off-target effects of RNAi. ACS Chem Biol 2006; 1: 274-6.
96. F. Czauderna, M. Fechtner, Dames S, et al., Structural variations and stabilising modifi-938 cations of synthetic si RNAs in mammalian cells, Nucleic Acids Res 2013; 31: 2705-16.
97. P.D. Cook. Medicinal chemistry of antisense oligonucleotides-future opportunities. Anticancer Drug Des 1991; 6: 585-607.
98. Lennox KA, Behlke MA. A direct comparison of anti-micro RNA oligonucleotide potency. Pharm Res 2010; 27: 1788-99.
99. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of micro RNA-122 in primates with chronic hepatitis C virus infection 2010; 327: 198-201.
100. Elmén J, Lindow M, Schütz S, et al. "LNA-mediated micro RNA silencing in non-human primates.". Nature 2008; 452: 896-9.
101. Lennox KA, Owczarzy R, Thomas DM, Walder JA, Behlke MA. Improved Performance of Anti-mi RNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids 2013; 2: e117.
102. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
103. Poltronieri P, D'Urso PI, Mezzolla V, et al. Potential of anti-cancer therapy based on anti-mi R-155 oligonucleotides in glioma and brain tumours. Chem Biol Drug Des 2013; 81: 79-84.
104. H. Lv, S. Zhang, Wang B, et al., Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006; 114: 100-9.
105. O.P. Medina, Y. Zhu, K. Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004; 10: 2981-9.
106. Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting sc Fv deliver si RNA and mi RNA for cancer therapy. Mol Ther 2010; 18: 1650-6.
107. Ebert MS, Neilson JR, Sharp PA. Micro RNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-6.
108. Lin CW, Chang YL, Chang YC, et al. Micro RNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun 2013; 4: 1877.
109. Esau CC. Inhibition of micro RNA with antisense oligonucleotides. Methods 2008; 44: 55-60.